Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Eye movement deficits in X-linked dystonia-parkinsonism are related to striatal degeneration.

Sprenger A, Hanssen H, Hagedorn I, Prasuhn J, Rosales RL, Jamora RDG, Diesta CC, Domingo A, Klein C, Brüggemann N, Helmchen C.

Parkinsonism Relat Disord. 2019 Apr;61:170-178. doi: 10.1016/j.parkreldis.2018.10.016. Epub 2018 Oct 15.

PMID:
30352750
2.

Benefits and Risks of Aliskiren Treatment in Patients With Type 2 Diabetes: Analyses of the 3A Registry.

Kistner I, Zeymer U, Dechend R, Hagedorn I, Riemer T, Bramlage P, Pittrow D, Senges J, Schmieder RE.

J Clin Hypertens (Greenwich). 2016 Oct;18(10):1045-1053. doi: 10.1111/jch.12828. Epub 2016 Apr 20.

3.

The Revolving Fund Pharmacy Model: backing up the Ministry of Health supply chain in western Kenya.

Manji I, Manyara SM, Jakait B, Ogallo W, Hagedorn IC, Lukas S, Kosgei EJ, Pastakia SD.

Int J Pharm Pract. 2016 Oct;24(5):358-66. doi: 10.1111/ijpp.12254. Epub 2016 Feb 23.

PMID:
26913925
4.

Assessing the accuracy of a point-of-care analyzer for hyperlipidaemia in western Kenya.

Park PH, Chege P, Hagedorn IC, Kwena A, Bloomfield GS, Pastakia SD.

Trop Med Int Health. 2016 Mar;21(3):437-44. doi: 10.1111/tmi.12653. Epub 2016 Jan 7.

5.

Platelet Gi protein Gαi2 is an essential mediator of thrombo-inflammatory organ damage in mice.

Devanathan V, Hagedorn I, Köhler D, Pexa K, Cherpokova D, Kraft P, Singh M, Rosenberger P, Stoll G, Birnbaumer L, Piekorz RP, Beer-Hammer S, Nieswandt B, Nürnberg B.

Proc Natl Acad Sci U S A. 2015 May 19;112(20):6491-6. doi: 10.1073/pnas.1505887112. Epub 2015 May 5.

6.

The impact of age on the benefits and risks of aliskiren treatment: analyses of the 3A registry.

Friedrich S, Zeymer U, Dechend R, Hagedorn I, Riemer T, Zemmrich C, Bramlage P, Pittrow D, Senges J, Schmieder RE.

J Hum Hypertens. 2015 May;29(5):316-23. doi: 10.1038/jhh.2014.86. Epub 2014 Oct 2.

PMID:
25273857
7.

Disproportional decrease in office blood pressure compared with 24-hour ambulatory blood pressure with antihypertensive treatment: dependency on pretreatment blood pressure levels.

Schmieder RE, Schmidt ST, Riemer T, Dechend R, Hagedorn I, Senges J, Messerli FH, Zeymer U.

Hypertension. 2014 Nov;64(5):1067-72. doi: 10.1161/HYPERTENSIONAHA.113.03140. Epub 2014 Aug 4.

PMID:
25259741
8.

Ambulatory blood pressure monitoring: is it mandatory for blood pressure control in treated hypertensive patients?: prospective observational study.

Lehmann MV, Zeymer U, Dechend R, Kaiser E, Hagedorn I, Deeg E, Senges J, Schmieder RE.

Int J Cardiol. 2013 Oct 3;168(3):2255-63. doi: 10.1016/j.ijcard.2013.01.209. Epub 2013 Mar 7.

PMID:
23474245
9.

Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice.

Bender M, May F, Lorenz V, Thielmann I, Hagedorn I, Finney BA, Vögtle T, Remer K, Braun A, Bösl M, Watson SP, Nieswandt B.

Arterioscler Thromb Vasc Biol. 2013 May;33(5):926-34. doi: 10.1161/ATVBAHA.112.300672. Epub 2013 Feb 28.

10.

Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature.

Kleinschnitz C, Kraft P, Dreykluft A, Hagedorn I, Göbel K, Schuhmann MK, Langhauser F, Helluy X, Schwarz T, Bittner S, Mayer CT, Brede M, Varallyay C, Pham M, Bendszus M, Jakob P, Magnus T, Meuth SG, Iwakura Y, Zernecke A, Sparwasser T, Nieswandt B, Stoll G, Wiendl H.

Blood. 2013 Jan 24;121(4):679-91. doi: 10.1182/blood-2012-04-426734. Epub 2012 Nov 15.

11.

Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction.

Frantz S, Hofmann U, Fraccarollo D, Schäfer A, Kranepuhl S, Hagedorn I, Nieswandt B, Nahrendorf M, Wagner H, Bayer B, Pachel C, Schön MP, Kneitz S, Bobinger T, Weidemann F, Ertl G, Bauersachs J.

FASEB J. 2013 Mar;27(3):871-81. doi: 10.1096/fj.12-214049. Epub 2012 Nov 16.

PMID:
23159933
12.

Redundant functions of phospholipases D1 and D2 in platelet α-granule release.

Thielmann I, Stegner D, Kraft P, Hagedorn I, Krohne G, Kleinschnitz C, Stoll G, Nieswandt B.

J Thromb Haemost. 2012 Nov;10(11):2361-72. doi: 10.1111/j.1538-7836.2012.04924.x.

13.

Altered microtubule equilibrium and impaired thrombus stability in mice lacking RanBP10.

Meyer I, Kunert S, Schwiebert S, Hagedorn I, Italiano JE Jr, Dütting S, Nieswandt B, Bachmann S, Schulze H.

Blood. 2012 Oct 25;120(17):3594-602. doi: 10.1182/blood-2012-01-401737. Epub 2012 Aug 30.

14.

Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis.

Pleines I, Hagedorn I, Gupta S, May F, Chakarova L, van Hengel J, Offermanns S, Krohne G, Kleinschnitz C, Brakebusch C, Nieswandt B.

Blood. 2012 Jan 26;119(4):1054-63. doi: 10.1182/blood-2011-08-372193. Epub 2011 Nov 1.

15.

Genetic and antibody-induced glycoprotein VI deficiency equally protects mice from mechanically and FeCl(3) -induced thrombosis.

Bender M, Hagedorn I, Nieswandt B.

J Thromb Haemost. 2011 Jul;9(7):1423-6. doi: 10.1111/j.1538-7836.2011.04328.x. No abstract available.

16.

Arterial thrombus formation. Novel mechanisms and targets.

Hagedorn I, Vögtle T, Nieswandt B.

Hamostaseologie. 2010 Aug;30(3):127-35. Review.

PMID:
20680230
17.

Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding.

Hagedorn I, Schmidbauer S, Pleines I, Kleinschnitz C, Kronthaler U, Stoll G, Dickneite G, Nieswandt B.

Circulation. 2010 Apr 6;121(13):1510-7. doi: 10.1161/CIRCULATIONAHA.109.924761. Epub 2010 Mar 22.

PMID:
20308613
18.

Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation.

Kleinschnitz C, Schwab N, Kraft P, Hagedorn I, Dreykluft A, Schwarz T, Austinat M, Nieswandt B, Wiendl H, Stoll G.

Blood. 2010 May 6;115(18):3835-42. doi: 10.1182/blood-2009-10-249078. Epub 2010 Mar 9.

19.

Multiple alterations of platelet functions dominated by increased secretion in mice lacking Cdc42 in platelets.

Pleines I, Eckly A, Elvers M, Hagedorn I, Eliautou S, Bender M, Wu X, Lanza F, Gachet C, Brakebusch C, Nieswandt B.

Blood. 2010 Apr 22;115(16):3364-73. doi: 10.1182/blood-2009-09-242271. Epub 2010 Feb 4.

20.

Impaired alpha(IIb)beta(3) integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1.

Elvers M, Stegner D, Hagedorn I, Kleinschnitz C, Braun A, Kuijpers ME, Boesl M, Chen Q, Heemskerk JW, Stoll G, Frohman MA, Nieswandt B.

Sci Signal. 2010 Jan 5;3(103):ra1. doi: 10.1126/scisignal.2000551.

21.

CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis.

May F, Hagedorn I, Pleines I, Bender M, Vögtle T, Eble J, Elvers M, Nieswandt B.

Blood. 2009 Oct 15;114(16):3464-72. doi: 10.1182/blood-2009-05-222273. Epub 2009 Jul 29.

22.

HLö 7 dimethanesulfonate, a potent bispyridinium-dioxime against anticholinesterases.

Eyer P, Hagedorn I, Klimmek R, Lippstreu P, Löffler M, Oldiges H, Spöhrer U, Steidl I, Szinicz L, Worek F.

Arch Toxicol. 1992;66(9):603-21.

PMID:
1482283
23.

The bispyridinium-dioxime HLö-7. A potent reactivator for acetylcholinesterase inhibited by the stereoisomers of tabun and soman.

de Jong LP, Verhagen MA, Langenberg JP, Hagedorn I, Löffler M.

Biochem Pharmacol. 1989 Feb 15;38(4):633-40.

PMID:
2917018
24.

Study on the stability of the oxime HI 6 in aqueous solution.

Eyer P, Hagedorn I, Ladstetter B.

Arch Toxicol. 1988;62(2-3):224-6.

PMID:
3196158
25.

Stability study of HI-6 dichloride in various anticholinergic formulations.

Brown ND, Gray RR, Stermer-Cox MG, Doctor BP, Hagedorn I.

J Chromatogr. 1984 Dec 19;315:389-94. No abstract available.

PMID:
6526905
26.

Interactions of bisquaternary pyridine salts (H-oximes) with cholinergic receptors.

Kuhnen-Clausen D, Hagedorn I, Gross G, Bayer H, Hucho F.

Arch Toxicol. 1983 Nov;54(3):171-9.

PMID:
6661028
27.

Synthesis of pyridinium analogues of acetylcholine and their interactions with intestinal muscarinic receptors.

Kuhnen-Clausen D, Hagedorn I, Bill R.

J Med Chem. 1979 Feb;22(2):177-80.

PMID:
423196
28.

[Reactivation of phosphorylated acetylcholinesterase. Isomeric bisquaternary salts of pyridine aldoximes].

Hagedorn I, Stark I, Schoene K, Schenkel H.

Arzneimittelforschung. 1978;28(11):2055-7. German.

PMID:
582905
29.
30.

[Synthesis and Quaternation of Pyridine-aldoxim Alkylethers (author's transl)].

Hagedorn I, Gündel WH, Hoose J, Jenter C.

Arzneimittelforschung. 1976;26(7):1273-5. German.

PMID:
1036912
31.

[Betaines of quaternary salts of pyridine-2-and -4-aldoxim (author's transl)].

Hagedorn I, Gündel WH.

Arzneimittelforschung. 1976;26(5):753-5. German.

PMID:
786301
32.

Reactivation of phosphorylated acetylcholinesterase--dependence upon activator acidity.

Hagedorn I, Stark I, Lorenz HP.

Angew Chem Int Ed Engl. 1972 Apr;11(4):307-9. No abstract available.

PMID:
4626426
33.

[Reactivation of phosphorylated acetylcholine esterase with oximes: contribution to the study of the reaction course].

Hagedorn I, Gündel WH, Schoene K.

Arzneimittelforschung. 1969 Apr;19(4):603-6. German. No abstract available.

PMID:
5819160
34.
36.

[Structural explanation of xanthocillin; a new antibiotic].

HAGEDORN I, TONJES H.

Pharmazie. 1957 Sep;12(9):567-80. German. No abstract available.

PMID:
13494165
37.

[Structure of xanthocillin, a new antibiotic].

HAGEDORN I, TONJES H.

Pharmazie. 1956 Jun;11(6):409-10. German. No abstract available.

PMID:
13370319

Supplemental Content

Loading ...
Support Center